Sandbox Reserved 1726: Difference between revisions
No edit summary |
No edit summary |
||
| Line 35: | Line 35: | ||
== Inhibition, Regulation, and Future Pathways == | == Inhibition, Regulation, and Future Pathways == | ||
The regulation of ALK dimerization by ALKAL points to one clear way of inhibiting ALK activity and may offer new therapeutic strategies in multiple disease settings <ref name="Li">PMID:34819665</ref | The regulation of ALK dimerization by ALKAL points to one clear way of inhibiting ALK activity and may offer new therapeutic strategies in multiple disease settings <ref name="Li">PMID:34819665</ref>. As the dimerization of ALK is essential for activation of this protein, the inhibition of this activation is a potent way of inhibiting further ALK activity.<ref name ="Li" /> The inhibition and regulation of this extracellular region of ALK is actively being explored, as this part of ALK is part of what distinguishes it from other RTKs, like LTK. Researchers are currently exploring the use of [https://proteopedia.org/wiki/index.php/Antibody antibodies] as a means of inhibiting the activity of ALK through the extracellular domain. The use of inhibitory antibodies in preclinical studies has shown effective at reducing ALKAL ligand binding significantly, and efficiently prevents ALK from interacting with ALKAL. | ||
ALK can also be regulated in the extracellular domains by its own ligands. The different qualities of ALKAL1 and ALKAL2 make them both unique ligands for ALK, and both have different qualities in their interactions with ALK. | |||
</StructureSection>. | |||
== References == | == References == | ||
<references/> | <references/> | ||